CXCL13 and psoriasis: Emerging studies have also found that CXCL13 can be served as a potential biomarker for other autoimmune diseases and autoimmune-related disorders such as type 1 diabetes mellitus (T1DM), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), Graves’ disease (GD), bullous pemphigoid (BP), psoriasis, systemic sclerosis (SSc), autoimmune pancreatitis (AIP), and common variable immunodeficiency (CVID).